Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
RBC, BMO Sell Moneris in C$2B Deal, Keep Payment Ties
RBC and BMO have agreed to sell Moneris Solutions to Francisco Partners for C$2 billion, with RBC expecting an after-tax gain of about C$475 million. The banks will maintain long-term referral agreements.
Take-Two Climbs as GTA VI Hype Fuels $8.1B Bookings Forecast
Take-Two Interactive (TTWO) shares jumped 2.87% to $253.57 on strong volume, extending gains after Q1 results beat guidance. The company reaffirmed its fiscal 2027 bookings forecast of $8.0-$8.2 billion, driven by anticipation for Grand Theft Auto VI.
Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran
Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.
Tesla Stock Stalls Despite Retail Buying Surge as Valuation Hits 300x Earnings
Tesla shares remained nearly unchanged despite a tripling of retail purchases to $372 million, as valuation concerns persist with the stock trading at over 300 times earnings.
S&P 500 Options Sentiment Hits 4-Year Bullish Peak as Rally Loses Steam
S&P 500 call-to-put ratio hits 0.9, a four-year high, even as index slips. JPMorgan raises target to 8,000, but limited upside remains.
Lilly's Foundayo Wins UK Approval, Lifting Shares Nearly 3%
Eli Lilly's (LLY) shares jumped 2.9% after the UK became the first European country to approve its oral weight-loss drug Foundayo, adding about $30 billion to its market value.
Apple Drops $97B After Jefferies Downgrade on iPhone Concerns
Apple (AAPL) lost about $97 billion in market value after Jefferies downgraded the stock to Underperform, citing iPhone pricing and margin pressures.
Archer Aviation Soars 11% on Boeing Deal, Eyes $200M Revenue
Archer Aviation (ACHR) jumped 11% after agreeing to acquire Boeing's Insitu, Wisk, and SkyGrid, adding $200M in annual revenue and a strategic partnership.
Sionna Therapeutics Collapses 92% After Phase 2a Setback
Sionna Therapeutics (SION) tumbled 92% after its Phase 2a trial failed to meet the primary endpoint, pushing the market cap below its cash holdings. Vertex (VRTX) rose on reduced competitive risk.
